Latest Industry News & Trends

Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.

Recently Added News

5/1/2026
BreakingCataractCornealGlaucomaIOLLaserPharmaRetinaRevenueSurgical
Q1-2026 Ophthalmic Revenue Roundup for Bausch + Lomb, Regeneron, Glaukos, Astellas, Novartis, and Lumibird
Q1-2026 Ophthalmic Revenue Roundup for Bausch + Lomb, Regeneron, Glaukos, Astellas, Novartis, and Lumibird

Bausch + Lomb reported April 29 that its Q1-2026 revenue was $1.24 billion, a 9 percent increase (+6 percent cc) over $1.14 billion in Q1-2025. Surgical segment revenue was $228 million, a 7 percen...

5/1/2026
BreakingRetinaStudy
Scientists Deliver Healthy Mitochondria to Sick Cells, Including Eye Cells
Scientists Deliver Healthy Mitochondria to Sick Cells, Including Eye Cells

Swiss scientists reported April 15 that they had developed a technology that can deliver healthy mitochondria directly to cells most affected by disease. They called their approach a major step tow...

5/1/2026
BreakingDealsPharmaRetina
Ligand to Acquire Xoma, Including its Vabysmo Royalties, for $739 Million
Ligand to Acquire Xoma, Including its Vabysmo Royalties, for $739 Million

Jupiter, Florida-based Ligand Pharmaceuticals and Xoma Royalty Corporation, of Emeryville, California, announced April 27 that Ligand would acquire Xoma for $39 per share of common stock in cash, f...

5/1/2026
BreakingPharmaRegulationRetina
Belite Bio Initiates Rolling NDA Submission for Oral Tinlarebant in Stargardt
Belite Bio Initiates Rolling NDA Submission for Oral Tinlarebant in Stargardt

Belite Bio announced April 21 that it had initiated a rolling new drug application (NDA) submission to the US FDA for oral tinlarebant for the treatment of Stargardt disease. The San Diego, Califor...

5/1/2026
BreakingCataractEquipmentEuropeRegulationRetinaSurgical
BVI Announces Full CE Marking for its Virtuoso Platforms
BVI Announces Full CE Marking for its Virtuoso Platforms

BVI Medical reported April 20 that itsVirtuoso cataract-only and dual-function cataract-vitrectomy platforms had gained CE marking under the new European Union Medical Device Regulation (MDR). The ...

5/1/2026
BreakingCataractClinical TrialIOLPharma
US FDA Gives Green Light to Trial of LayerBio’s OcuRing-K for Post-op Inflammation and Pain
US FDA Gives Green Light to Trial of LayerBio’s OcuRing-K for Post-op Inflammation and Pain

Israel’s PRF Technologies and its majority-owned subsidiary LayerBio reported on April 28 that the US FDA had signed off on their investigational new drug (IND) application, allowing LayerBio to pr...

5/1/2026
BreakingCornealDry EyePharmaStudy
Formosa, Singapore Eye to Explore New Treatments for Corneal, Ocular Surface Disease
Formosa, Singapore Eye to Explore New Treatments for Corneal, Ocular Surface Disease

Taiwan’s Formosa Pharmaceuticals and the Singapore Eye Research Institute (SERI) have teamed up to address unmet needs in corneal and ocular surface disease, Formosa announced April 30. The partner...

5/1/2026
BreakingEuropeGene TherapyRegulationRetina
EMA Grants PRIME Designation to Ray Therapeutics’ Optogenetic RP Candidate
EMA Grants PRIME Designation to Ray Therapeutics’ Optogenetic RP Candidate

Ray Therapeutics announced April 29 that the European Medicines Agency had granted Priority Medicines (PRIME) designation to RTx-015, its optogenetic therapy candidate for retinitis pigmentosa (RP)...

4/24/2026
BreakingCataractGlaucomaLaserOptometryScope of Practice
New Law in Tennessee Expands ODs’ Scope to Include SLT, LPI, YAG Capsulotomy
New Law in Tennessee Expands ODs’ Scope to Include SLT, LPI, YAG Capsulotomy

Tennessee has become the 16th US state to pass a law expanding optometrists’ scope of practice to include in-office laser procedures. Senate Bill 2076, signed into law by Gov. Bill Lee on April 14,...

4/24/2026
BreakingFundingGene TherapyRetina
Inventors of Luxturna Win $3 Million Breakthrough Prize
Inventors of Luxturna Win $3 Million Breakthrough Prize

Penn Medicine’s Jean Bennett, MD, PhD, and Albert Maguire, MD, along with Katherine High, MD, of Children’s Hospital of Philadelphia (CHOP), have been awarded a prestigious Breakthrough Prize in Li...

4/24/2026
BreakingPharmaRetinaRevenue
Roche Reports Q1-2026 Vabysmo Sales of $1.3 Billion
Roche Reports Q1-2026 Vabysmo Sales of $1.3 Billion

Swiss company Roche reported April 23 that Vabysmo sales in Q1-2026 were CHF 1.024 billion ($1.3 billion, calculated for March 31, 2026), up 13 percent in constant currency from CHF 1.018 billion i...

4/21/2026
CataractIOLNewsletterOptometryPremium
New OD Survey Looks at Factors Shaping Premium IOL Education Before Referral
New OD Survey Looks at Factors Shaping Premium IOL Education Before Referral

Optometrists play an increasingly important role in educating patients about cataract surgery prior to referral, as those patients’ expectations continue to rise. Key findings from Market Scope’s i...

Past News Stories

4/24/2026
BiosimilarsBreakingCornealGlaucomaLaserRegulationRetina
US CMS Issues J-Codes and Q-Codes for Four Ophthalmic Products in Q1-2026
US CMS Issues J-Codes and Q-Codes for Four Ophthalmic Products in Q1-2026

The US Centers for Medicare and Medicaid Services (CMS) issued J-codes in Q1-2026 for Harrow’s Iopidine and Glaukos’ Epioxa and Epioxa HD. In addition, the CMS issued Q-codes for Zydec’s interchang...

4/24/2026
BreakingDealsDiagnosticGlaucomaOCTRetina
Revenio Group to Acquire Visionix in $341 Million Deal
Revenio Group to Acquire Visionix in $341 Million Deal

Finland’s Revenio Group, parent of ophthalmic diagnostic company iCare, announced April 13 that it would acquire France-based Visionix in a deal worth €290 million ($341 million). Revenio said that...

4/24/2026
BreakingPharmaRegulationRetina
US FDA Approves Vabysmo for Extended Dosing Beyond 6 Months in RVO
US FDA Approves Vabysmo for Extended Dosing Beyond 6 Months in RVO

Genentech announced April 9 that the US FDA had approved the extension of dosing intervals for Vabysmo (faricimab-svoa) beyond six months for patients with macular edema due to retinal vein occlusi...

4/24/2026
BreakingPharmaPresbyopiaRegulation
Lenz Submits Marketing Application for Vizz Presbyopia Drop in the UK
Lenz Submits Marketing Application for Vizz Presbyopia Drop in the UK

Lenz Therapeutics announced April 20 that it had submitted a marketing authorization application to the UK’s Medicines and Healthcare Products Regulatory Agency for Vizz, an eye drop targeting pres...

4/24/2026
BreakingChinaDealsGlaucomaPharma
Santen to Market Five of AbbVie’s Glaucoma Drops in China
Santen to Market Five of AbbVie’s Glaucoma Drops in China

Japan’s Santen Pharmaceutical announced April 17 that its China subsidiary had entered into a distribution and promotion agreement with AbbVie for five marketed glaucoma eye drops in the Chinese ma...

4/24/2026
BreakingIndustryMyopia
Theialife Names Ruggia as President, CEO, Readies Phase III Oral Myopia Candidate
Theialife Names Ruggia as President, CEO, Readies Phase III Oral Myopia Candidate

Theialife, of Dover, Delaware, announced April 23 that it had appointed Thomas Ruggia as president and chief executive officer. Theialife co-founder Sundeep Aurora will continue to oversee scientif...

4/21/2026
AcquisitionsDealsNewsletterRetina
Cencora Expands Reach in Retina Care with Acquisition of EyeSouth Partners
Cencora Expands Reach in Retina Care with Acquisition of EyeSouth Partners

Cencora’s agreement to purchase the retinal business of EyeSouth Partners for $1.1 billion is the company’s second major acquisition in an aggressive campaign to become a major, vertically integrat...

4/21/2026
DeviceEuropeNewsletterRegulation
EU Softens Stance on MDR Transition to Ensure Availability of Needed Devices
EU Softens Stance on MDR Transition to Ensure Availability of Needed Devices

Implementation of the European Union’s Medical Device Regulation (MDR) has proven more complex and prolonged than originally anticipated. The new standards took effect in May 2021, ending a four-ye...

4/21/2026
Dry EyeGlaucomaNewsletter
Nanodropper Bottle Tip Adaptor Goes from Simple Idea to Global Product
Nanodropper Bottle Tip Adaptor Goes from Simple Idea  to Global Product

Mu Medical has been turning heads for years with claims that its Nanodropper bottle tip adaptor cuts typical eye drop volume more than 60 percent, resulting in a single medicine bottle lasting seve...

4/21/2026
AcquisitionsDealsFundingNewsletter
Fundraising Slows in Q1-2026 for Ophthalmic Firms
Fundraising Slows in Q1-2026 for Ophthalmic Firms

Market Scope identified 17 ophthalmic deals in Q1-2026, down from 21 in Q1-2025. Fundraising totals reached $856.6 million, a decline from $930.2 million in Q1-2025. The number of deals was below t...

4/21/2026
AcquisitionsDealsNewsletterRetina
Biogen to Acquire Apellis for $5.6 Billion with Eye Toward Growth
Biogen to Acquire Apellis for $5.6 Billion with Eye Toward Growth

Biogen reported March 31 that it had agreed to acquire Apellis Pharmaceuticals, maker of Syfovre, for about $5.6 billion in cash to expand its portfolio of rare-disease medicines. Under the deal, e...

4/21/2026
AcquisitionsDealsInstrumentsNewsletter
Halma Acquires Surgistar to Augment MST’s Ophthalmic Instrument Portfolio
Halma Acquires Surgistar to Augment MST’s Ophthalmic Instrument Portfolio

UK-based Halma, the parent of ophthalmic instrument maker MicroSurgical Technology (MST) announced April 13 that it had acquired Surgistar, of Vista, California, as an add-on to MST. No financial d...

Want to Read the Full Article?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more